Controlling AAV tropism in the nervous system with natural and engineered capsids

Methods in Molecular Biology

Volumn 1382, Issue , 2016, Pages 133-149

  Castle, Michael J ^a   Turunen, Heikki T ^a   Vandenberghe, Luk H ^a   Wolfe, John H ^a  

^a NONE

Author keywords

AAV; Adeno associated virus; Capsid; Gene delivery; Gene therapy; Serotype; Vector; Virus

Indexed keywords

PARVOVIRUS VECTOR;

NERVOUS SYSTEM; NONHUMAN; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS CAPSID; VIRUS GENOME; VIRUS RECOMBINATION; ADMINISTRATION AND DOSAGE; ANIMAL; ANTIBODY SPECIFICITY; CENTRAL NERVOUS SYSTEM; CHEMISTRY; DEPENDOPARVOVIRUS; GENE TRANSFER; GENE VECTOR; HUMAN; PHYSIOLOGY; RETINA; VIROLOGY;

ANIMALS; CAPSID; CENTRAL NERVOUS SYSTEM; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; ORGAN SPECIFICITY; RETINA; VIRAL TROPISM;

EID: 84948844867     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3271-9_10     Document Type: Chapter

References (131)

1. Hermonat PL, Muzyczka N (1984) Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A 81: 6466–6470
2. Samulski RJ, Berns KI, Tan M, Muzyczka N (1982) Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A 79:2077–2081
3. Samulski RJ, Chang LS, Shenk T (1987) A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 61:3096–3101
4. Tratschin JD, West MH, Sandbank T, Carter BJ (1984) A human parvovirus, adenoassociated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol 4:2072–2081
5. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X et al (2004) Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381–6388
6. Gao G, Vandenberghe LH, Wilson JM (2005) New recombinant serotypes of AAV vectors. Curr Gene Ther 5:285–297
7. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ (2006) Alpha2,3 and alpha2,6 N-linked sialic acids facilitate effi cient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80:9093–9103
8. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA (2001) Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and effi cient transduction but differ in sialic acid linkage specifi city. J Virol 75:6884–6893
9. Summerford C, Samulski RJ (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438–1445
10. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA (2006) The 37/67-kilodalton laminin receptor is a receptor for adenoassociated virus serotypes 8, 2, 3, and 9. J Virol 80:9831–9836
11. Bell CL, Vandenberghe LH, Bell P, Limberis MP, Gao GP, Van Vliet K et al (2011) The AAV9 receptor and its modifi cation to improve in vivo lung gene transfer in mice. J Clin Invest 121:2427–2435
12. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A (2011) Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286:13532–13540
13. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A (1999) Human fi broblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5:71–77
14. Summerford C, Bartlett JS, Samulski RJ (1999) AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5:78–82
15. Pilz IH, Di Pasquale G, Rzadzinska A, Leppla SH, Chiorini JA (2012) Mutation in the platelet-derived growth factor receptor alpha inhibits adeno-associated virus type 5 transduction. Virology 428:58–63
16. Howard DB, Powers K, Wang Y, Harvey BK (2008) Tropism and toxicity of adenoassociated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. Virology 372:24–34
17. Royo NC, Vandenberghe LH, Ma JY, Hauspurg A, Yu L, Maronski M et al (2008) Specifi c AAV serotypes stably transduce primary hippocampal and cortical cultures with high effi ciency and low toxicity. Brain Res 1190:15–22
18. Bartlett JS, Samulski RJ, McCown TJ (1998) Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 9:1181–1186
19. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential effi ciency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302–317
20. Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH (2003) Intraventricular brain injection of adenoassociated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-defi cient mice. J Virol 77:7034–7040
21. Cearley CN, Wolfe JH (2006) Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13:528–537
22. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA et al (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 97:3428–3432
23. Klein RL, Dayton RD, Tatom JB, Henderson KM, Henning PP (2008) AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purifi cation method. Mol Ther 16:89–96
24. Hutson TH, Verhaagen J, Yanez-Munoz RJ, Moon LD (2012) Corticospinal tract transduction: a comparison of seven adeno- associated viral vector serotypes and a non-integrating lentiviral vector. Gene Ther 19:49–60
25. Liu G, Martins IH, Chiorini JA, Davidson BL (2005) Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Ther 12:1503–1508
26. Lawlor PA, Bland RJ, Mouravlev A, Young D, During MJ (2009) Effi cient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17:1692–1702
27. Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, Zweig RM (2006) Effi cient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fl uorescent proteins. Mol Ther 13:517–527
28. Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ (2007) Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15:1504–1511
29. Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L et al (2007) Comparative analysis of adenoassociated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18: 195–206
30. Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM et al (2007) Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 Rhesus macaque-derived adeno-associated virus vector. Mol Ther 15:481–491
31. Vite CH, Passini MA, Haskins ME, Wolfe JH (2003) Adeno-associated virus vectormediated transduction in the cat brain. Gene Ther 10:1874–1881
32. Passini MA, Watson DJ, Wolfe JH (2004) Gene delivery to the mouse brain with adeno- associated virus. Methods Mol Biol 246:225–236
33. Peng SP, Kugler S, Ma ZK, Shen YQ, Schachner M (2011) Comparison of AAV2 and AAV5 in gene transfer in the injured spinal cord of mice. Neuroreport 22:565–569
34. Cearley CN, Wolfe JH (2007) A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 27:9928–9940
35. Li SF, Wang RZ, Meng QH, Li GL, Hu GJ, Dou WC et al (2006) Intra-ventricular infusion of rAAV1-EGFP resulted in transduction in multiple regions of adult rat brain: a comparative study with rAAV2 and rAAV5 vectors. Brain Res 1122:1–9
36. Cearley CN, Vandenberghe LH, Parente MK, Carnish ER, Wilson JM, Wolfe JH (2008) Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther 16:1710–1718
37. Gray SJ, Nagabhushan KS, McCown TJ, Jude SR (2013) Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in nonhuman primates. Gene Ther 20:450–459
38. Samaranch L, Salegio EA, San SW, Kells AP, Bringas JR, Forsayeth J et al (2013) Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fl uid of nonhuman primates. Hum Gene Ther 24:526–532
39. Jacques SJ, Ahmed Z, Forbes A, Douglas MR, Vigenswara V, Berry M et al (2012) AAV8(gfp) preferentially targets large diameter dorsal root ganglion neurones after both intra-dorsal root ganglion and intrathecal injection. Mol Cell Neurosci 49:464–474
40. Snyder BR, Gray SJ, Quach ET, Huang JW, Leung CH, Samulski RJ et al (2011) Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther 22:1129–1135
41. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59–65
42. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ (2011) Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19:1058–1069
43. Yang B, Li S, Wang H, Guo Y, Gessler DJ, Cao C et al (2014) Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther 22:1299–1309
44. Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R et al (2011) Several rAAV vectors effi - ciently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 19:1440–1448
45. Towne C, Raoul C, Schneider BL, Aebischer P (2008) Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 16:1018–1025
46. Fu H, Muenzer J, Samulski RJ, Breese G, Sifford J, Zeng X et al (2003) Selfcomplementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther 8:911–917
47. Chen SJ, Sanmiguel J, Lock M, McMenamin D, Draper C, Limberis MP et al (2013) Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia. Hum Gene Ther Clin Dev 24:154–160
48. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J et al (2005) Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12:1072–1082
49. Le Meur G, Stieger K, Smith AJ, Weber M, Deschamps JY, Nivard D et al (2007) Restoration of vision in RPE65-defi cient Briard dogs using an AAV serotype 4 vector that specifi cally targets the retinal pigmented epithelium. Gene Ther 14:292–303
50. Stieger K, Colle MA, Dubreil L, Mendes- Madeira A, Weber M, Le Meur G et al (2008) Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Mol Ther 16:916–923
51. Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM (2008) Novel AAV serotypes for improved ocular gene transfer. J Gene Med 10:375–382
52. Lei B, Zhang K, Yue Y, Ghosh A, Duan D (2009) Adeno-associated virus serotype-9 effi ciently transduces the retinal outer plexiform layer. Mol Vis 15:1374–1382
53. Vandenberghe LH, Bell P, Maguire AM, Xiao R, Hopkins TB, Grant R et al (2013) AAV9 targets cone photoreceptors in the nonhuman primate retina. PLoS One 8:e53463
54. Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al (2011) Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 3:88ra54
55. Boye SE, Alexander JJ, Boye SL, Witherspoon CD, Sandefer KJ, Conlon TJ et al (2012) The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specifi c expression in the primate retina. Hum Gene Ther 23:1101–1115
56. Hollis ER 2nd, Kadoya K, Hirsch M, Samulski RJ, Tuszynski MH (2008) Effi cient retrograde neuronal transduction utilizing selfcomplementary AAV1. Mol Ther 16:296–301
57. Castle MJ, Gershenson ZT, Giles AR, Holzbaur EL, Wolfe JH (2014) Adenoassociated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport. Hum Gene Ther 25(8):705–20
58. Castle MJ, Perlson E, Holzbaur EL, Wolfe JH (2014) Long-distance axonal transport of AAV9 is driven by dynein and kinesin-2 and is traffi cked in a highly motile Rab7-positive compartment. Mol Ther 22:554–566
59. Klaw MC, Xu C, Tom VJ (2013) Intraspinal AAV injections immediately rostral to a thoracic spinal cord injury site effi ciently transduces neurons in spinal cord and brain. Mol Ther Nucleic Acids 2, e108
60. Masamizu Y, Okada T, Ishibashi H, Takeda S, Yuasa S, Nakahara K (2010) Effi cient gene transfer into neurons in monkey brain by adeno-associated virus 8. Neuroreport 21:447–451
61. Schaffer DV, Koerber JT, Lim KI (2008) Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 10:169–194
62. Morizono K, Chen IS (2011) Receptors and tropisms of envelope viruses. Curr Opin Virol 1:13–18
63. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ (1999) Targeted adenoassocia ted virus vector transduction of nonpermissive cells mediated by a bispecifi c F(ab’gamma)2 antibody. Nat Biotechnol 17:181–186
64. Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M Jr (2002) Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol 76: 12900–12907
65. Le HT, Yu QC, Wilson JM, Croyle MA (2005) Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J Control Release 108:161–177
66. Carlisle RC, Benjamin R, Briggs SS, Sumner- Jones S, McIntosh J, Gill D et al (2008) Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J Gene Med 10:400–411
67. Horowitz ED, Weinberg MS, Asokan A (2011) Glycated AAV vectors: chemical redirection of viral tissue tropism. Bioconjug Chem 22:529–532
68. Rabinowitz JE, Samulski RJ (2000) Building a better vector: the manipulation of AAV virions. Virology 278:301–308
69. Hauck B, Chen L, Xiao W (2003) Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 7:419–425
70. Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM (2010) Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson’s disease. Mol Neurodegener 5:43
71. Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski RJ (2004) Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defi nes subgroups. J Virol 78:4421–4432
72. Yang Q, Mamounas M, Yu G, Kennedy S, Leaker B, Merson J et al (1998) Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum Gene Ther 9:1929–1937
73. Opie SR, Warrington KH, Agbandje- McKenna M, Zolotukhin S, Muzyczka N (2003) Identifi cation of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77:6995–7006
74. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J et al (1999) Genetic capsid modifi cations allow effi cient re-targeting of adeno-associated virus type 2. Nat Med 5:1438
75. Shi W, Arnold GS, Bartlett JS (2001) Insertional mutagenesis of the adenoassociated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 12:1697–1711
76. Wu P, Xiao W, Conlon T, Hughes J, Agbandje- McKenna M, Ferkol T et al (2000) Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74:8635–8647
77. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R et al (2001) Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 3:964–975
78. Warrington KH Jr, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N (2004) Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 78:6595–6609
79. Gigout L, Rebollo P, Clement N, Warrington KH Jr, Muzyczka N, Linden RM et al (2005) Altering AAV tropism with mosaic viral capsids. Mol Ther 11:856–865
80. Judd J, Wei F, Nguyen PQ, Tartaglia LJ, Agbandje-McKenna M, Silberg JJ et al (2012) Random insertion of mCherry Into VP3 domain of adeno-associated virus yields fl uorescent capsids with no loss of infectivity. Mol Ther Nucleic Acids 1:e54
81. Yu CY, Yuan Z, Cao Z, Wang B, Qiao C, Li J et al (2009) A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther 16:953–962
82. Lee NC, Falk DJ, Byrne BJ, Conlon TJ, Clement N, Porvasnik S et al (2012) An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery. Genet Vaccines Ther 10:3
83. Ying Y, Muller OJ, Goehringer C, Leuchs B, Trepel M, Katus HA et al (2010) Hearttargeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther 17:980–990
84. White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED et al (2004) Targeted gene delivery to vascular tissue in vivo by tropism-modifi ed adeno-associated virus vectors. Circulation 109:513–519
85. Work LM, Buning H, Hunt E, Nicklin SA, Denby L, Britton N et al (2006) Vascular bed-targeted in vivo gene delivery using tropism- modifi ed adeno-associated viruses. Mol Ther 13:683–693
86. White K, Buning H, Kritz A, Janicki H, McVey J, Perabo L et al (2008) Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther 15:443–451
87. Michelfelder S, Kohlschutter J, Skorupa A, Pfennings S, Muller O, Kleinschmidt JA et al (2009) Successful expansion but not complete restriction of tropism of adenoassociated virus by in vivo biopanning of random virus display peptide libraries. PLoS One 4:e5122
88. Michelfelder S, Varadi K, Raupp C, Hunger A, Korbelin J, Pahrmann C et al (2011) Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS One 6:e23101
89. Chen YH, Chang M, Davidson BL (2009) Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15:1215–1218
90. Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH et al (2013) In vivodirected evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 5:189ra176
91. Shi W, Bartlett JS (2003) RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfateindependent cell entry mechanism. Mol Ther 7:515–525
92. Kern A, Schmidt K, Leder C, Muller OJ, Wobus CE, Bettinger K et al (2003) Identifi cation of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77:11072–11081
93. Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS et al (2008) Engineering and selection of shuffl ed AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 16:1252–1260
94. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV (2006) Directed evolution of adenoassociated virus yields enhanced gene delivery vectors. Nat Biotechnol 24:198–204
95. Yang L, Jiang J, Drouin LM, Agbandje- McKenna M, Chen C, Qiao C et al (2009) A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffl ing and in vivo selection. Proc Natl Acad Sci U S A 106: 3946–3951
96. Excoffon KJ, Koerber JT, Dickey DD, Murtha M, Keshavjee S, Kaspar BK et al (2009) Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci U S A 106:3865–3870
97. Li W, Zhang L, Johnson JS, Zhijian W, Grieger JC, Ping-Jie X et al (2009) Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther 17: 2067–2077
98. Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV (2009) A novel adeno-associated viral variant for effi cient and selective intravitreal transduction of rat Muller cells. PLoS One 4:e7467
99. Koerber JT, Klimczak R, Jang JH, Dalkara D, Flannery JG, Schaffer DV (2009) Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 17:2088–2095
100. Maguire CA, Gianni D, Meijer DH, Shaket LA, Wakimoto H, Rabkin SD et al (2010) Directed evolution of adeno-associated virus for glioma cell transduction. J Neurooncol 96:337–347
101. Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, McCown TJ et al (2010) Directed evolution of a novel adenoassociated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther 18:570–578
102. Jang JH, Koerber JT, Kim JS, Asuri P, Vazin T, Bartel M et al (2011) An evolved adenoassociated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol Ther 19:667–675
103. Asuri P, Bartel MA, Vazin T, Jang JH, Wong TB, Schaffer DV (2012) Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther 20:329–338
104. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R et al (2010) Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 28:79–82
105. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS et al (2012) Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20:443–455
106. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ (2006) Single amino acid changes can infl uence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol 80:11393–11397
107. Vandenberghe LH, Breous E, Nam HJ, Gao G, Xiao R, Sandhu A et al (2009) Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther 16:1416–1428
108. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM (2009) Transduction effi ciencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 17:294–301
109. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R et al (2006) Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol 80:821–834
110. Li C, Diprimio N, Bowles DE, Hirsch ML, Monahan PE, Asokan A et al (2012) Single amino acid modifi cation of adeno-associated virus capsid changes transduction and humoral immune profi les. J Virol 86:7752–7759
111. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M et al (2008) Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-effi ciency transduction at lower doses. Proc Natl Acad Sci U S A 105: 7827–7832
112. Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Sun J et al (2013) Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One 8: e62097
113. Li M, Jayandharan GR, Li B, Ling C, Ma W, Srivastava A et al (2010) High-effi ciency transduction of fi broblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum Gene Ther 21:1527–1543
114. Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M et al (2008) Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular traffi cking and transgene expression. Virology 381:194–202
115. Petrs-Silva H, Dinculescu A, Li Q, Min SH, Chiodo V, Pang JJ et al (2009) Higheffi ciency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 17:463–471
116. Petrs-Silva H, Dinculescu A, Li Q, Deng WT, Pang JJ, Min SH et al (2011) Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 19:293–301
117. Iida A, Takino N, Miyauchi H, Shimazaki K, Muramatsu S (2013) Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice. Biomed Res Int 2013:974819
118. Zolotukhin I, Luo D, Gorbatyuk O, Hoffman B, Warrington K, Herzog R et al (2013) Improved adeno-associated viral gene transfer to Murine glioma. J Genet Syndr Gene Ther 4
119. Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R et al (2013) Bioengineering of AAV2 capsid at specifi c serine, threonine, or lysine residues improves its transduction effi ciency in vitro and in vivo. Hum Gene Ther Methods 24:80–93
120. Nathanson JL, Yanagawa Y, Obata K, Callaway EM (2009) Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors. Neuroscience 161:441–450
121. Xu R, Janson CG, Mastakov M, Lawlor P, Young D, Mouravlev A et al (2001) Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specifi c gene cassettes. Gene Ther 8:1323–1332
122. Kugler S, Lingor P, Scholl U, Zolotukhin S, Bahr M (2003) Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 311:89–95
123. Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J et al (2011) Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 22:1143–1153
124. Husain T, Passini MA, Parente MK, Fraser NW, Wolfe JH (2009) Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters. Gene Ther 16:927–932
125. von Jonquieres G, Mersmann N, Klugmann CB, Harasta AE, Lutz B, Teahan O et al (2013) Glial promoter selectivity following AAV-delivery to the immature brain. PLoS One 8:e65646
126. Paterna JC, Moccetti T, Mura A, Feldon J, Bueler H (2000) Infl uence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther 7:1304–1311
127. Kingsman SM, Mitrophanous K, Olsen JC (2005) Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther 12:3–4
128. Schambach A, Bohne J, Baum C, Hermann FG, Egerer L, von Laer D et al (2006) Woodchuck hepatitis virus post- transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther 13:641–645
129. Geisler A, Jungmann A, Kurreck J, Poller W, Katus HA, Vetter R et al (2011) microRNA122-regulated transgene expression increases specifi city of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther 18:199–209
130. Karali M, Manfredi A, Puppo A, Marrocco E, Gargiulo A, Allocca M et al (2011) MicroRNA-restricted transgene expression in the retina. PLoS One 6:e22166
131. Qiao C, Yuan Z, Li J, He B, Zheng H, Mayer C et al (2011) Liver-specifi c microRNA-122 target sequences incorporated in AAV vectors effi ciently inhibits transgene expression in the liver. Gene Ther 18:403–410